GHO Capital Partners and Ampersand Capital Partners announced the closing of the previously announced acquisition of Avid Bioservices (CDMO). On 7 November, GHO and Ampersand entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1B. With the completion of the transaction, Avid’s stockholders are entitled to receive $12.50 per share in cash. The Company’s common stock has ceased trading and will be delisted from Nasdaq.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDMO:
- Avid Bioservices Approves Merger with Space Finco
- Avid Bioservices’ stockholders approve transaction with GHO and Ampersand
- Avid Bioservices says ISS, Glass Lewis recommend vote ‘FOR’ transaction
- Avid Bioservices announces expiration of HSR waiting period for acquisition
- Avid Bioservices Reports Revenue Growth Amid Acquisition Plans